Paradigm Biocapital Advisors Increases Holdings in Olema Pharmaceuticals by 750,000 Shares, Raising Position to 4.5% of Reportable AUM

Paradigm Biocapital Advisors has increased its holdings in Olema Pharmaceuticals by 750,000 shares in Q4 2025, raising the position to 4.5% of its reportable AUM. The quarter-end value of the Olema Pharmaceuticals stake stood at $122.09 million. Olema Pharmaceuticals shares are priced at $14.08, up 242% over the past year, outperforming the S&P 500's roughly 15% gain in the same period.